Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.

ABSTRACT:

Purpose

Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients.

Experimental design

We conducted an international retrospective cohort study of patients with TRK fusion-driven central nervous system tumors.

Results

A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared

SUBMITTER: Lamoureux AA 

PROVIDER: S-EPMC11788648 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature